Dapagliflozin in Mangement of Pulmonary Hypertension Patients

Sponsor
Assiut University
Study ID
NCT06612086
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pulmonary Hypertension

Eligibility Criteria

Sex
ALL
Age
18 Months - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin (Forxiga) — DRUG
    we study effect of dapagliflozin on patient with pulmonary hypertension by follow up RV function and prognosis of life of patient

Study Details

Effect of SGLT2 (Dapagliflozin)on prognosis of patient with pulmonary Hypertension and Effect on RV function By speckle tract echocardiography at Assiut University Hospital.

Key Dates

Start date
Oct 25, 2024
Status verified
Oct 2024
Primary completion
Sep 10, 2025
Completion
Oct 10, 2026

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: we follow up patient who take Dapagliflozin in patient with pulmonary hypertension
    we follow up patient who take Dapagliflozin in patient with pulmonary hypertension

Primary Outcome Measure

Effect of Dapagliflozin on Right ventricle systolic function in patient with pulmonary Hypertension by speckle tract Echocardiography(RV Strain ) [ Time Frame: 6 month ]

Related Studies